Tip:
Highlight text to annotate it
X
>>>Dr. Margileth: When tamoxifen was first developed in the early 80s it replaced removal
of the ovaries as a hormone manipulation for the treatment of breast cancer. The initial
trials looked at two years of tamoxifen versus no tamoxifen and two years was better than
none. The next trial was a trial of five years versus two years and five years turned out
to be a better length of treatment than two years. The next trial I did was a trial of
ten years versus five years and interestingly ten years did not turn out to be better than
five years. So the standard approach at this point in time would be to limit tamoxifen
use after primary surgery for breast cancer to five years. If the patient has a particularly
bad breast cancer and is post menopausal, one can then ask the question whether further
treatment with an aromatase inhibitor is appropriate, but in general five years of tamoxifen would
be the time period of giving that drug. *****
Hi, I am Dr. Jay Harness and I want to share with you an important information that I believe
that every newly diagnosed patient with breast cancer needs to know.
Susan Denver: “I am a breast cancer survivor.”
Katherine Stockton: “I am a breast cancer survivor.”
Coree: “I am a breast cancer survivor…”
Susan Denver: “…and I want every woman to know…”
Katherine Stockton: “…about personalized breast cancer treatment…”
Susan Denver: “…and the Genomic Test.”
Coree: “A test that helps guide a woman and her doctor…”
Katherine Stockton: “…to the best treatment options for her.”
Susan Denver: “Pass it on!”